FDA Enters Public-Private Partnership To Evaluate COVID-19 Tests Amidst Concerns Over Efficacy
The US FDA is partnering with industry stakeholders and advocacy groups to investigate the long-term effectiveness of COVID-19 tests. The announcement follows recent moves by the agency to pull a slew of antibody tests from the market due to a high rate of false negatives and criticism from stakeholders, including lawmakers.
You may also be interested in...
US FDA principal deputy commissioner Amy Abernethy is set to leave the agency by the end of April. The surprise news comes in the midst of the Biden administration still figuring out who they want to lead the FDA.
The test, which can be processed in 83 minutes or less, has shown 100% sensitivity and 100% specificity in clinical trials, according to the New Jersey company.
US FDA commissioner Stephen Hahn said during an 18 June “fireside chat” that he expects closer relationships with industry and a greater reliance on postmarket data to continue even after the COVID-19 pandemic comes to an end.